Drug combo before surgery for early breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug (SHR-A1811) alone or with letrozole given before surgery to shrink early-stage breast cancer that is hormone receptor-positive and HER2-low. It may help make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have been diagnosed with early-stage (stage II or III) invasive breast cancer that has not spread to distant organs.
- Your cancer is hormone receptor-positive (ER or PR positive) and HER2-low.
- You have not had any prior treatment for breast cancer (like chemotherapy, radiation, or hormone therapy).
- You are generally healthy with normal organ function and an ECOG performance status of 0 or 1.
- You are willing to use effective birth control and not become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three HER2-targeted drugs with a CDK4/6 inhibitor before surgery for breast cancer that is both HER2-positive and ER-positive. It aims to see if this approach shrinks tumors more effectively and is safe.
This trial tests a new combination of treatments given before surgery for hormone receptor positive, HER2 negative breast cancer. It uses stereotactic body radiation therapy (SBRT), chemotherapy, and an investigational drug called AK112 to shrink tumors and make surgery easier.
This study tests whether giving two drugs (SHR-A1811 and pertuzumab) before surgery can shrink HER2-positive breast cancer tumors. It aims to see if this combination improves treatment outcomes for patients with stage II or III disease.
This study tests a new combination of treatments given before surgery for breast cancer that is hormone-receptor positive and HER2-low. The goal is to see if giving these drugs before surgery can shrink tumors and improve outcomes. You might be eligible if you have not yet had any treatment for breast cancer.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests giving chemotherapy before surgery to shrink breast tumors, which may make surgery easier or allow breast-conserving options. It is for adults with invasive breast cancer that has not spread to distant organs.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.